Comorbidities in Children with COVID-19 and MIS-C/PIMS-TS and Risk Factors for Hospitalization, Severe Disease, Intensive Care and Death

Abstract

This narrative review sums up data from the SARS-CoV-2-pandemia on preexisting disease/underlying conditions/comorbidities and risk factors in children for severe COVID-19 and MIS-C/PIMS-TS as well as hospitalization and mortality. Young infants and adolescents are at highest risk of hospital and PICU admission. Two or more comorbidities rather than single entities pose a risk for more severe courses of SARS-CoV-2 infection in children. Asthma and malignancy do not increase complication rates. MIS-C/PIMS-TS is not associated with any specific underlying disease.

COVID-19 in pediatric lung transplant recipients: Clinical course and outcome

“…In contrast to previous studies on adult lung transplant recipients, which show a high rate of hospitalization and death 9 , 10 , 11 , 12 , 13 , 14 , we did not observe any severe disease or deaths related to SARS-CoV-2 infection. Furthermore, no long-term effects or graft related complications occurred within the observation period, although preexisting comorbidities and immunosuppressive regimens in our cohort are comparable to previously described adult lung transplant populations 4 , 5 . This observation supports previous findings that age is one of the main risk factors for severe COVID-19 1,2 .…”

COVID-19 in Hospitalized Children: A Single-Center Retrospective Study of 604 patients

“…Both of them had MIS-C. The current data about the severity of SARS-COV-2-induced disease suggests that the clinical course is much milder in children than in adults, the data that we gathered are also suggestive of [11][12][13][14][15][16].…”